Infant pertussis and maternal immunity: The curious case of Canada

Vaccine ◽  
2021 ◽  
Author(s):  
Natasha S. Crowcroft ◽  
Shelly Bolotin ◽  
Ye Li ◽  
Helen Campbell ◽  
Gayatri Amirthalingam
Keyword(s):  
Maternal Immunity

scholarly journals Do Micronutrient and Omega-3 Fatty Acid Supplements Affect Human Maternal Immunity during Pregnancy? A Scoping Review

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 367
Author(s):  
Gail Rees ◽  
Louise Brough ◽  
Gustavo Moya Orsatti ◽  
Anna Lodge ◽  
Steven Walker
Keyword(s):  
Immune System ◽  
Scoping Review ◽  
Hiv Infections ◽  
Cochrane Library ◽  
Limited Attention ◽  
Clinical Effects ◽  
Omega 3 ◽  
Maternal Immunity ◽  
Human Trials ◽  
General Terms

Maternal dietary micronutrients and omega-3 fatty acids support development of the fetal and neonatal immune system. Whether supplementation is similarly beneficial for the mother during gestation has received limited attention. A scoping review of human trials was conducted looking for evidence of biochemical, genomic, and clinical effects of supplementation on the maternal immune system. The authors explored the literature on PubMed, Cochrane Library, and Web of Science databases from 2010 to the present day using PRISMA-ScR methodology. Full-length human trials in English were searched for using general terms and vitamin A, B12, C, D, and E; choline; iodine; iron; selenium; zinc; and docosahexaenoic/eicosapentaenoic acid. Of 1391 unique articles, 36 were eligible for inclusion. Diverse biochemical and epigenomic effects of supplementation were identified that may influence innate and adaptive immunity. Possible clinical benefits were encountered in malaria, HIV infections, anemia, Type 1 diabetes mellitus, and preventing preterm delivery. Only limited publications were identified that directly explored maternal immunity in pregnancy and the effects of micronutrients. None provided a holistic perspective. It is concluded that supplementation may influence biochemical aspects of the maternal immune response and some clinical outcomes, but the evidence from this review is not sufficient to justify changes to current guidelines.

scholarly journals Maternal Immunity in Suckling Pigs with a Solubilized Aujeszky's Disease Virus Trial Vaccine

1992 ◽  
Vol 45 (6) ◽  
pp. 383-387
Author(s):  
KENICHI YOSHIKI ◽  
AKIRA IWAMOTO ◽  
TADASHI HIRAHARA ◽  
AKIHIRO IZUMIDA ◽  
SATOYUKI OTA ◽  
...  
Keyword(s):  
Disease Virus ◽  
Maternal Immunity ◽  
Aujeszky's Disease ◽  
Aujeszky’S Disease ◽  
Aujeszky’S Disease Virus

scholarly journals Transfer of maternal immunity to piglets is involved in early protection against Mycoplasma hyosynoviae infection

2017 ◽  
Vol 183 ◽  
pp. 22-30 ◽  
Author(s):  
K. Tølbøll Lauritsen ◽  
T. Hagedorn-Olsen ◽  
G. Jungersen ◽  
U. Riber ◽  
H. Stryhn ◽  
...  
Keyword(s):  
Maternal Immunity ◽  
Mycoplasma Hyosynoviae

Transfer of maternal immunity project

2021 ◽  
Author(s):  
Amrullah
Keyword(s):  
Oreochromis Niloticus ◽  
Nile Tilapia ◽  
Maternal Immunity ◽  
Polyvalent Vaccine ◽  
Nile Tilapia Oreochromis Niloticus ◽  
Offspring Protection

This preprint is a part of the article "Transfer of maternal immunity using a polyvalent vaccine and offspring protection in Nile tilapia, Oreochromis niloticus"

scholarly journals Rotavirus C: prevalence in suckling piglets and development of virus-like particles to assess the influence of maternal immunity on the disease development

2019 ◽  
Vol 50 (1) ◽  
Author(s):  
Juliet Chepngeno ◽  
Annika Diaz ◽  
Francine C. Paim ◽  
Linda J. Saif ◽  
Anastasia N. Vlasova
Keyword(s):  
Cell Culture ◽  
Diarrheal Disease ◽  
Economic Losses ◽  
Disease Development ◽  
Fecal Samples ◽  
Virus Like Particles ◽  
Maternal Immunity ◽  
The Us ◽  
Suckling Piglets ◽  
Major Impediment

Abstract Rotavirus C (RVC) has been detected increasingly in humans and swine in different countries, including the US. It is associated with significant economic losses due to diarrheal disease in nursing piglets. In this study we aimed: (1) to determine the prevalence of RVC in healthy and diarrheic suckling piglets on US farms; and (2) to evaluate if maternal antibody (Ab) levels were associated with protection of newborn suckling piglets against RVC. There was a significantly higher prevalence (p = 0.0002) of litters with diarrhea born to gilts compared with those born to multiparous sows. Of 113 nursing piglet fecal samples tested, 76.1% were RVC RNA positive. Fecal RVC RNA was detected in significantly (p = 0.0419) higher quantities and more frequently in piglets with diarrhea compared with healthy ones (82.5 vs. 69.9%). With the exception of the historic strain Cowden (G1 genotype), field RVC strains do not replicate in cell culture, which is a major impediment for studying RVC pathogenesis and immunity. To circumvent this, we generated RVC virus-like particles (VLPs) for Cowden (G1), RV0104 (G3) and RV0143 (G6) and used them as antigens in ELISA to detect swine RVC Abs in serum and milk from the sows. Using RVC-VLP Ab ELISA we demonstrated that sows with diarrheic litters had significantly lower RVC IgA and IgG Ab titers in milk compared to those with healthy litters. Thus, our data suggest that insufficient lactogenic protection provided by gilts plays a key role in the development of and the increased prevalence of clinical RVC disease.

scholarly journals Impact of Maternal Immunity on Congenital Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review

Vaccines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 129 ◽  
Author(s):  
Coppola ◽  
Mangold ◽  
Cantrell ◽  
Permar
Keyword(s):  
Systematic Review ◽  
Primary Infection ◽  
Vaccine Development ◽  
Transmission Rate ◽  
Systemic Review ◽  
Maternal Infection ◽  
Chronic Infections ◽  
Congenital Cytomegalovirus ◽  
Birth Prevalence ◽  
Maternal Immunity

Congenital cytomegalovirus (cCMV) is the leading non-genetic cause of sensorineural hearing loss (SNHL), and efforts are geared towards prevention through vaccine development. Transmission rates following primary maternal infection occur at rates of 30–40%, however reported placental rates upon non-primary maternal infection is reported to be less than <4%. There is significant debate about whether this reduction in transmission rate is due to pre-existing maternal immunity, which could identify possible immunologic targets for vaccines. To address this question, we performed a systemic review of the literature using Preferred Reporting Items for Systematic Review and Analysis (PRISMA) guidelines. We identified cohort studies in high CMV seroprevalent (>80%) areas or in developing regions that examined a cohort of at least 50 infants for congenital CMV acquisition. We identified 19 articles that met criteria and were further categorized based on pre-conception serology, maternal seroprevalence, or previously known seroprevalence. Birth prevalence rates ranged from 0.4% to 6% (median 1.1%), with the studies reporting on clinical outcome (16/19 studies) noting the majority of infected infants as asymptomatic. We also utilized a recent study that differentiated primary maternal infections from chronic infections in a highly seropositive population to calculate a placental transmission rate in women with pre-existing immunity compared to that of no pre-existing immunity. This work confirms a low cCMV birth prevalence in highly seropositive populations, indicates via a calculated placental transmission rate that the CMV placental transmission rate is lower in non-primary infection than that of primary infection, and reveals gaps in data for further research aiming to identify targets for vaccine development.

Sign in / Sign up

Export Citation Format

Share Document